Clinical trials: gemcitabine hydrochloride
Urothelial Carcinoma, Kidney Cancer
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
This is a phase 2 study of the drug denosumab for the management bone metastases from urothelial cancer. The purpose of this study is to find out how effective denosumab is in the management of bone metastases from urothelial…
- Conditions
- Urothelial Carcinoma, Kidney Cancer, Ureter Cancer, Bladder Cancer
- Trial name
- NCT03520231
- Testing
- Denosumab, Gemcitabine, Carboplatin
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- University Health Network, Toronto
Lung Neoplasms
Low-frequency Rotating Magnetic System Combined With Systemic Anti-tumor Therapy for Advanced Lung Cancer
The purpose of this study is to determine whether Low-frequency Rotating Magnetic Therapy System is effective and safe in the treatment of advanced lung cancer.
- Trial name
- NCT02701231
- Testing
- Low-frequency Rotating Magnetic Therapy System, Systemic anti-tumor therapy
- Where
- 4 sites in China
- Volunteers
- 200 people
- Sponsor
- Chinese PLA General Hospital
Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
This phase III trial compares the effect of decreased number of radiation (ultra-hypofractionated) treatments to the usual radiation number of treatments (hypofractionation) with standard of care chemotherapy, with cisplatin…
- Conditions
- Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
- Trial name
- NCT07097142
- Testing
- Biospecimen Collection, Cisplatin, Computed Tomography
- Where
- 259 sites in United States, Canada
- Volunteers
- 486 people
- Sponsor
- NRG Oncology
Sarcoma, Soft Tissue
Study of Gemcitabine and Vinorelbine in Soft Tissue Sarcomas
The purpose of this study is to determine if the combination of gemcitabine and vinorelbine is effective in treating patients with advanced soft tissue sarcoma.
- Trial name
- NCT00134641
- Testing
- gemcitabine, vinorelbine
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Dana-Farber Cancer Institute
Recurrent Pancreatic Cancer
Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer
To evaluate the efficacy of Tislelizumab combined with Nab-paclitaxel and Gemcitabine in the treatment of recurrent pancreatic cancer
- Trial name
- NCT04902261
- Testing
- Tislelizumab, Nab paclitaxel, Gemcitabine
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Changhai Hospital
Nasopharyngeal Cancer Recurrent, Nasopharyngeal Cancinoma (NPC)
Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) is an endemic malignancy in Southern China and southeast Asia. Despite intensive radical therapy, between 15% and 30% of NPC patients develop relapse.
- Trial name
- NCT07129772
- Testing
- Gemcitabine (GEM), Cisplatin, PEMBROLIZUMAB (alone or when added to a regimen above)
- Where
- Hong Kong
- Volunteers
- 53 people
- Sponsor
- The University of Hong Kong
Pancreatic Ductal Adenocarcinoma
BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
The purpose of this research study is to learn more about a new combination of drugs being given to treat pancreatic cancer. The drugs being tested are BMS-813160, nivolumab, gemcitabine, and nab-paclitaxel.
- Trial name
- NCT03496662
- Testing
- BMS-813160, Nivolumab, Gemcitabine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Metastatic Pancreatic Cancer
Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer
The purpose of this study is to determine whether S-1 is effective as 2nd line therapy in slowing tumor activity in patients with metastatic pancreatic cancer who have previously received 1st line treatment with a gemcitabine…
- Trial name
- NCT00652054
- Testing
- S-1
- Volunteers
- 39 people
- Sponsor
- Taiho Oncology, Inc.
Malignant Pleural Mesothelioma, Mesothelioma
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
The purpose of this study is to determine whether the transarterial chemoperfusion treatment with cisplatin, methotrexate and gemcitabine is safe and effective in adults with malignant pleural mesothelioma (MPM).
- Trial name
- NCT02611037
- Testing
- Cisplatin, Methotrexate, Gemcitabine
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Urothelial Carcinoma, Bladder Cancer
Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer
This is a pre-surgical study involving subjects with muscle invasive bladder urothelial cancer, who are candidates for cisplatin ineligible neoadjuvant therapy. It is a one-arm phase II study in single center.
- Trial name
- NCT04553939
- Testing
- Toripalimab, Gemcitabine
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Henan Cancer Hospital
Pancreatic Cancer
Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy
This randomized trial examines the effectiveness of chemoradiotherapy compared to chemotherapy alone after induction chemotherapy with 3 cycles of gemcitabine or 6 cycles of FOLFIRINOX in patients with locally advanced, non…
- Trial name
- CONKO-007 (NCT01827553)
- Testing
- Induction chemotherapy with gemcitabine or FOLFIRINOX, Radiotherapy, 28 x 1.8 Gy, Chemotherapy, gemcitabine
- Where
- 23 sites in Germany
- Volunteers
- 830 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Pancreatic Adenocarcinoma, Metastatic
Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer
A phase IIb, open-label, randomized study of Nab-Paclitaxel and Gemcitabine and plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer
- Trial name
- VIRAGE (NCT05673811)
- Testing
- Nab-paclitaxel, Gemcitabine, VCN-01
- Where
- 17 sites in United States, Spain
- Volunteers
- 112 people
- Sponsor
- Theriva Biologics SL
Non-small Cell Lung Cancer
Evaluating Efficacy and Safety of Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy
The aim of this study is to investigate the efficacy and safety of Tarceva versus combination of Gemcitabine plus Cisplatin as neoadjuvant treatment in patients with stage IIIA-N1,N2 NSCLC with EGFR activating mutation in exon 19…
- Trial name
- NCT01297101
- Testing
- Erlotinib
- Sponsor
- Shanghai Chest Hospital
Breast Cancer
LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006007
- Testing
- gemcitabine hydrochloride, pemetrexed disodium
- Where
- 24 sites in United States, Canada
- Volunteers
- 59 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Nasopharyngeal Neoplasms
Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma
The purpose of this study is to compare individualized clinical target volume (CTV) based on disease extension risk atlas and computer-aided delineation with traditional CTV in intensity modulated radiotherapy (IMRT) for…
- Trial name
- NCT02627807
- Testing
- IMRT using individualized CTV, IMRT using traditional CTV, Gemcitabine and cisplatin (induction chemotherapy)
- Where
- China
- Volunteers
- 386 people
- Sponsor
- Sun Yat-sen University
Cachexia, Pancreatic Neoplasms
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related Cachexia
The purpose of this study is to evaluate the effectiveness and safety of infliximab, the active ingredient in Remicade, for the treatment of cachexia in pancreatic cancer patients who are receiving chemotherapy with gemcitabine.
- Trial name
- NCT00060502
- Testing
- Infliximab; Gemcitabine
- Volunteers
- 73 people
- Sponsor
- Centocor, Inc.
Solid Tumor, Gastric Cancer
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
This study was planned as an open-label, multi-site, Phase I/IIa dose escalation, safety, and pharmacokinetic (PK) trial of BNT141 followed by expansion cohorts in patients with Claudin 18.2 (CLDN18.2)-positive tumors.
- Conditions
- Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT04683939
- Testing
- BNT141, Nab-paclitaxel, Gemcitabine
- Where
- 7 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- BioNTech SE
Treatment
Different Patterns of Target Delineation in SBRT for Locally Advanced Pancreatic Cancer
The purpose of this study is to compare the efficacy and safety of a recurrence-pattern-based-volume versus conventional-volume stereotactic body radiation therapy for locally advanced pancreatic cancer, so as to determine…
- Trial name
- NCT04699539
- Testing
- SBRT, Chemotherapy
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Changhai Hospital
Myeloma
High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma
The goal of this clinical research study is to learn if the combination of gemcitabine, busulfan, and melphalan, when given before a stem cell transplant, can help to control refractory myeloma.
- Trial name
- NCT01237951
- Testing
- Palifermin, Dexamethasone, Gemcitabine
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- M.D. Anderson Cancer Center
Locally Advanced Pancreatic Cancer, Irreversible Electroporation
Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer
Background Pancreatic cancer is one the leading causes of cancer-related death in Canada. Approximately 40 percent of patients with pancreatic cancer present with locally advanced pancreatic cancer and are not candidate for…
- Trial name
- SMART (NCT04276857)
- Testing
- Irreversible electroporation (NanoKnife® )
- Where
- 2 sites in Canada
- Volunteers
- 27 people
- Sponsor
- University of Saskatchewan
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.